{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:33:44Z","timestamp":1783110824704,"version":"3.54.6"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurolymphomatosis frequently impairs physical function, rendering patients unable to tolerate chimeric antigen receptor T-cell therapy (CAR-T). An alternative treatment strategy which can cross the blood-nerve barrier is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>\n                      A 64-year-old woman had a history of\n                      <jats:italic>MYD88L265P<\/jats:italic>\n                      mutated diffuse large B-cell lymphoma (DLBCL) successfully treated with Pola-R-CHP plus high-dose methotrexate one year prior. However, she developed progressive muscle weakness in her limbs, with a three-month history. Upon admission, she was bedridden, unable to resist gravity, and experienced bladder and rectal disturbances. Imaging studies revealed neurolymphomatosis involving the bilateral trigeminal nerves, cervical\/brachial plexus, brachial nerves, lumbosacral plexus, and femoral nerves. Ibrutinib 560 mg\/day combined with rituximab led to complete remission, and she regained the ability to walk within three months. Unfortunately, neurolymphomatosis relapsed after six months of ibrutinib treatment. Epcoritamab led to another complete remission, with a progression-free survival of six months. The adverse events were manageable, including Grade 1 cytokine release syndrome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This report is the first to demonstrate the effectiveness of epcoritamab in treating neurolymphomatosis. Bispecific antibodies may serve as a valuable bridging therapy for CAR-T, helping to restore their physical function. Bruton\u2019s tyrosine kinase inhibitors could also be an option for\n                      <jats:italic>MYD88L265P<\/jats:italic>\n                      mutated disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1738551","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:28:22Z","timestamp":1773293302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton\u2019s tyrosine kinase inhibitor and bispecific antibody therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Mitsuaki","family":"Oura","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Toho","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Salinas","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminari","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Uehara","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikako","family":"Tabata","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kameda Medical Center, Kamogawa","place":["Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/5.2.104","article-title":"Neurolymphomatosis","volume":"5","author":"Baehring","year":"2003","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-258210","article-title":"Neurolymphomatosis: an international primary CNS lymphoma collaborative group report","volume":"115","author":"Grisariu","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-02586-7","article-title":"Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis","volume":"109","author":"Kobayashi","year":"2019","journal-title":"Int J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27045","article-title":"Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes","volume":"62","author":"Keddie","year":"2020","journal-title":"Muscle Nerve"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003666","article-title":"Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era","volume":"5","author":"Khurana","year":"2021","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209698","article-title":"Clinical presentation, management, and outcome in neurolymphomatosis: A systematic review","volume":"103","author":"Kaulen","year":"2024","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27505","article-title":"Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis","volume":"99","author":"Kaulen","year":"2024","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for Malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2022","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40478-024-01763-6","article-title":"Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model","volume":"12","author":"Lim","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27316","article-title":"CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285613","article-title":"Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy","volume":"110","author":"Mercadal","year":"2025","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008553","article-title":"Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed\/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China","volume":"12","author":"Yu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.012","article-title":"Chimeric antigen receptor T - cell therapy for large B-cell lymphoma patients with central nervous system involvement, a systematic review and meta-analysis","volume":"24","author":"Elgohary","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.025692","article-title":"Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated ZO-1","volume":"75","author":"Kanda","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123022","article-title":"The role of endothelial dysfunction in peripheral blood nerve barrier: molecular mechanisms and pathophysiological implications","volume":"20","author":"Maiuolo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/JBM.S459123","article-title":"Clinical and genomic profile of primary cranial neurolymphomatosis","volume":"15","author":"Wolf","year":"2024","journal-title":"J Blood Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025355","article-title":"Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response","volume":"145","author":"Tumuluru","year":"2025","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e449_70094","DOI":"10.1002\/hon.70094_449","article-title":"449 | Bridging to CAR-T cell therapy in large B-cell lymphoma with either conventional therapy or the CD3xCD20 bispecific antibody glofitamab","volume":"43","author":"Schleifenbaum","year":"2025","journal-title":"Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1738551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:28:23Z","timestamp":1773293303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1738551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1738551"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1738551","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1738551"}}